GH Research PLC (NASDAQ: GHRS) released its financial results for the full year ended December 31, 2022, revealing R&D expenses were $20.5 million, a 138% increase compared to $8.6 million for the full year 2021. The increase was primarily due to increased activities relating to our technical development, clinical trials and increased employee expenses to support these activities.
Full Year 2022 Financial Highlights
-
Cash, cash equivalents and marketable securities were $251.7 million as of December 31, 2022, compared to cash of $276.8 million as of December 31, 2021. Marketable securities are comprised of investment grade bonds. The company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements …